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Abstract
Background: Utilisation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and
guide sheath (EBUS-GS) for diagnosis and staging of lung cancer is gaining popularity, however, its impact on
clinical practice is unclear. This study aimed to determine the impact of the introduction of endobronchial
ultrasound-guided procedures (EBUS) on time to management decision for lung cancer patients, and on the
utilisation of other invasive diagnostic modalities, including CT-guided trans-thoracic needle aspiration (CT-TTNA),
bronchoscopy, and mediastinoscopy.
Methods: Hospital records of new primary lung cancer patients presenting in 2007 and 2008 (Pre-EBUS cohort) and
in 2010 and 2011 (Post-EBUS cohort) were reviewed retrospectively.
Results: The Pre-EBUS cohort included 234 patients. Of the 326 patients in the Post-EBUS cohort, 90 had an EBUS
procedure (EBUS-TBNA for 19.0 % and EBUS-GS for 10.4 % of cases). The number of CT-TTNAs and bronchoscopies
decreased following the introduction of EBUS (p = 0.015 and p < 0.001 respectively). Of 162 CT-TTNAs, 59 (36 %)
resulted in complications compared to 1 complication each for bronchoscopy and EBUS-GS, and no complications
from EBUS-TBNA. Fewer complications occurred overall in the Post-EBUS cohort compared to the Pre-EBUS cohort
(p = 0.0264). The median time to management decision was 17 days (IQR 24) for the Pre-EBUS and 13 days (IQR 21) for
the Post-EBUS cohort (p = 0.07). Within the Post-EBUS cohort, median time to management decision was longer for the
EBUS group (n = 90) than the Non-EBUS group (17 days (IQR 29) vs. 10 days (IQR 10), p < 0.001). For half of EBUS-TBNA
patients (n = 28, 50.0 %) and EBUS-GS patients (n = 14, 50.0 %), EBUS alone provided sufficient diagnostic and/or
staging information; these patients had median time to management decision of 10 days. Regression analysis revealed
that the number of imaging events, inpatient, and outpatient visits were significant predictors of time to management
decision of >28 days; EBUS was not a predictor of time to management decision.
Conclusions: The introduction of EBUS led to fewer CT-TTNAs and bronchoscopies and did not impact on the time to
management decision. EBUS-TBNA or EBUS-GS alone provided sufficient information for diagnosis and/or regional
staging in half of the lung cancer patients referred for this investigation.
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Background
The management of lung cancer has changed considerably
over the last 5 to 10 years, with the recognition that Non-
Small Cell Lung Cancer (NSCLC) is a heterogeneous dis-
ease in terms of its histopathology, molecular pathology,
clinical manifestation, and response to treatment [1, 2].
Chemotherapeutic regimens are now tailored to the histo-
logical phenotype and targeted therapies are available for
certain molecular pathologies [2, 3]. Consequently, tissue
is required for accurate characterisation of the tumour
and staging remains important for determining the appro-
priate treatment and for guiding prognosis.
Whilst non-invasive procedures such as computed
tomography (CT), positron emission tomography (PET),
and PET-CT provide information about extra-thoracic
spread of tumours, their sensitivity and specificity for
staging localised and regional disease such as hilar or
mediastinal lymph node involvement is relatively poor
[4–7]. Mediastinoscopy has been the gold standard for
determining mediastinal lymph node status, but is vari-
ably performed [7, 8]. Conventional or ‘blind’ transbron-
chial needle aspiration (TBNA) of hilar and mediastinal
lymph nodes gives inconsistent results and has not been
routinely conducted [9].
The more recent advent of ultrasound-guided endo-
scopic procedures provides visualisation of structures on
the outside of the lumen wall, thereby allowing more ac-
curate sampling of tissue. Endobronchial ultrasound
(EBUS) and oesophageal ultrasound (EUS) procedures
utilise a linear probe which provides a fan-shaped ultra-
sound image in which the sampling needle can be seen in
real time, thus allowing more accurate sampling of medi-
astinal and hilar lymph nodes. These procedures perform
at least as well as mediastinoscopy [10]. EBUS transbron-
chial needle aspiration (EBUS-TBNA) - known as linear
EBUS - also has the potential to sample lymph nodes at
the hilum that are inaccessible to mediastinoscopy.
Over the last several decades, there has been a shift in
the histology of NSCLC from squamous cell carcinoma,
which tends to involve more central airways, to adenocar-
cinoma that is often located in the lung periphery, where
approximately 70 % of NSCLC is now found [11]. In the
past, sampling of such lesions was done by standard bron-
choscopy with fluoroscopic guidance, which has a poor
yield [12, 13]; CT guided transthoracic needle aspiration
(CT-TTNA), which has a better yield but may result in
complications such as pneumothorax [14]; or surgical re-
section, which carries some morbidity. Bronchoscopy using
a radial ultrasound probe with guide sheath (EBUS-GS)–
known as radial EBUS—has the potential to provide a simi-
lar diagnostic yield to CT-TTNA but with fewer complica-
tions such as pneumothorax [14].
Studies into the modalities used to diagnose lung can-
cer have shown a reduction in the number of CT-
TTNAs following the introduction of EBUS-GS [14] and
a reduction in the number of mediastinoscopies and
bronchoscopies following the introduction of EBUS-
TBNA [15]. However, to our knowledge, no study has
simultaneously explored the impact of EBUS on all diag-
nostic procedures undertaken, complications arising
from the various modalities, and changes to time taken
from first presentation to diagnosis following the intro-
duction of EBUS.
This study aimed to compare the number and type of
procedures undertaken to diagnose and stage lung can-
cer, the time between first presentation at the hospital
and establishment of a management decision, and the
incidence of complications arising from diagnostic pro-
cedures before and after the introduction of EBUS.
Methods
We conducted a retrospective pre-post study of all new
primary lung cancer cases presented to the lung cancer
Multi-Disciplinary Team Meeting (MDM) at a tertiary
hospital in Western Australia, between 1 January 2007
and 31 December 2008 (Pre-EBUS cohort) and between 1
January 2010 and 31 December 2011 (Post-EBUS cohort).
EBUS was introduced at the hospital at the end of 2008
and this hospital was the only site in the state where EBUS
procedures were performed at the time. Patients’ medical
records and hospital data were reviewed. Patients were ex-
cluded if their case was not discussed at the lung cancer
MDM. While cases with both initial investigation and
treatment performed outside the hospital were excluded,
patients were included if they had had some imaging and/
or invasive procedures performed elsewhere but were pre-
sented to the lung cancer MDM for diagnosis and
management.
The following data were collected: demographic de-
tails; co-morbidities (Charlson Index) [16]; performance
status (Eastern Co-operative Oncology Group Perform-
ance Status (ECOG-PS)) [17]; date of first presentation
at the hospital; invasive diagnostic procedures including
bronchoscopies (bronchoscopy refers to flexible bron-
choscopy with bronchial brushing, washing, biopsies,
and/or “blind” TBNA), CT-TTNA, EBUS, mediastinos-
copy; ultrasound-guided-FNA; endoscopic ultrasound-
guided-fine needle aspirations (EUS-FNA); date of pro-
cedures and resulting complications; stage of cancer;
date of initial treatment decision; and date of MDM dis-
cussion(s). In addition, all occasions of services related
to the lung cancer diagnosis were recorded, such as radi-
ology/imaging investigations, outpatient visits, day case
visits, inpatient visits, and visits to the accident and
emergency department.
Clinical stage of the Pre-EBUS cohort was based on the
6th edition of TNM staging [18], while the stage of the
Post-EBUS cohort was based on the 7th edition [19].
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When staging was not available, clinical stage was deter-
mined from hospital data and review of imaging by a re-
spiratory physician or respiratory fellow (authors MP and
SK). Cases without histological confirmation of their lung
cancer diagnosis (where diagnosis was based on imaging
and clinical presentation) were allocated to the NSCLC
subgroup for the purpose of analysis.
In most cases, patients were presented to our MDM
after an initial CT of the thorax and upper abdomen, and
in the majority of the cases results of a PET scan guided
recommendations for an EBUS-TBNA investigation.
EBUS procedures: Both EBUS-TBNA and -GS investi-
gations were performed under general anaesthesia or
moderate sedation. An on-site pathologist was present
to provide rapid on-site evaluation (ROSE) on EBUS-
TBNA procedures. The site and number of lymph node
stations sampled and the number of passes per lymph
node were determined by the operator. At least three
needle passes were made per lymph node unless the
diagnostic material was reported adequate on ROSE.
Statistical analysis
All statistical analyses were undertaken using IBM SPSS
Statistics 19 and STATA v 13. Pearson’s chi-squared ana-
lyses or Fisher’s exact tests were undertaken for between-
group comparisons for categorical variables (differences in
gender, smoking status, remoteness, tumour type, and sur-
gery between Pre-EBUS and Post-EBUS cohorts and
within the Post-EBUS cohort, the EBUS and non-EBUS
groups and for time to management decision (TMD)
<28 days for the Post-EBUS cohort and within the EBUS
group). Medians were calculated for continuous variables
and non-parametric tests (Mann–Whitney U tests) were
undertaken to compare groups (differences in age between
Pre-EBUS and Post-EBUS cohorts and within the Post-
EBUS cohort and the EBUS and non-EBUS groups; differ-
ences in the number of invasive diagnostic procedures,
total number of occasions of services, and time to man-
agement decisions for the Post-EBUS cohort and within
the EBUS group; and time to management decision within
EBUS-GS and EBUS-TBNA). Backwards stepwise logistic
regression was used to determine significant predictors of
the TMD within 28 days vs greater than 28 days, with
demographic variables (age, gender, remoteness), referral
source, Charlson index, ECOG-PS, EBUS procedure,
number of other invasive procedures, number of inpatient
and outpatient visits, number of imaging investigations
and stage of cancer initially entered into the model as po-
tential predictors.
Date of first presentation at the hospital was consid-
ered to be the first lung cancer-related hospital presenta-
tion date as either an inpatient or an outpatient. Date of
management decision was defined as the date of the
lung cancer MDM when the diagnosis was established
and/or the initial treatment decision was made. Time to
management decision (TMD) was defined as time from
first presentation at the hospital to date of MDM when
management decision was made. Patients referred to our
hospital for investigation of a lung mass were first seen
in a fast track clinic, held once weekly. EBUS bronchos-
copy sessions were approximately once weekly. Access
to PET was usually within 7 to 10 days. MDMs at our
institution are held on a weekly basis.
Ethics approval was obtained from the Sir Charles
Gairdner Group Human Research Ethics Committee (REF
No.2012-121) and the University of Western Australia
Ethics Committee (REF No. RA/4/1/5871). The need for
informed consent was waived by the Sir Charles Gairdner
Group Human Research Ethics Committee.
Results
Of 775 lung cancer patients presented to the lung cancer
MDM, 571 met the inclusion criteria: 245 in the Pre-
EBUS cohort and 326 in the Post-EBUS cohort (Fig. 1).
Eleven cases in the Pre-EBUS cohort underwent EBUS
and were excluded from the study as the respiratory
team was learning the new technique and in some cases
an additional procedure was performed to confirm the
EBUS result.
Patient characteristics
Both Pre-EBUS and Post-EBUS cohorts had similar pa-
tient characteristics (Table 1). Within the Post-EBUS co-
hort, no significant demographic differences were found
between the patients who had an EBUS investigation
(EBUS group) and those who did not (non-EBUS group)
(Table 1). There were significant differences between the
EBUS and non-EBUS group in terms of ECOG-PS (p =
0.009); EBUS was undertaken mainly for patients with
better performance status (ECOG-PS of 0 and 1).
Invasive procedures
The main invasive procedures in the Pre-EBUS cohort
were bronchoscopy and CT-TTNA, and in the Post-
EBUS cohort, bronchoscopy, CT-TTNA, and EBUS
(Table 2). There was a 17.5 % reduction in the propor-
tion of patients who had bronchoscopies (p < 0.001) and
a 10.2 % fall in the proportion of patients with CT-
TTNA (p = 0.012) following the introduction of EBUS-
TBNA and EBUS-GS. Mediastinoscopies were not rou-
tinely performed on lung cancer patients in either co-
hort; only one mediastinoscopy was performed in the
Pre-EBUS cohort and three in the Post-EBUS cohort. In
the Post-EBUS cohort, EBUS-TBNA was undertaken for
19.0 % of cases (n = 62) and EBUS-GS for 10.4 % of cases
(n = 34) (Table 3). EBUS-GS was utilised equally across
stages for NSCLC patients, but not used for any SCLC
patients. EBUS-TBNA was utilised equally across both
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Fig. 1 Cohort diagram of the study
Table 1 Patient characteristics of both cohorts, and of EBUS and Non-EBUS patients within the Post-EBUS cohort









Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age at diagnosis (years)a 69 (15) 69 (17) 67 (15) 70 (18)
n (%) n (%) n (%) n (%)
Male 139 (59.4) 200 (61.3) 58 (64.4) 142 (60.2)
Smoker
Unknown 18 (7.7) 32 (9.8) 8 (8.9) 24 (10.2)
Current 77 (32.9) 92 (28.2) 29 (32.2) 63 (26.7)
Ceased 124 (53.0) 180 (55.2) 49 (54.4) 131 (55.5)
Never 15 (6.4) 22 (6.7) 4 (4.4) 18 (7.6)
Remoteness
Major city 184 (79.3) 244 (74.8) 65 (72.2) 179 (75.8)
Inner regional 17 (7.3) 29 (8.9) 10 (11.1) 19 (8.1)
Outer regional 22 (9.5) 34 (10.4) 11 (12.2) 23 (9.7)
Remote 9 (3.9) 19 (5.8) 4 (4.4) 15 (6.4)
ECOG-PSb
0 87 (37.2) 91 (27.9) 25 (28.0) 66 (27.8)
1 78 (33.3) 143 (43.9) 50 (55.6) 93 (39.5)
2 43 (18.4) 58 (17.8) 13 (14.4) 45 (19.1)
3 20 (8.5) 28 (8.6) 2 (2.2) 26 (11.0)
4 6 (2.6) 6 (1.8) 0 (0.0) 6 (2.0)
Tumour type
NSCLC 204 (87.2) 288 (88.3) 80 (88.9) 208 (88.1)
SCLC 30 (12.8) 38 (11.7) 10 (11.0) 28 (11.9)
aMann–Whitney U test; all others except bare Pearson’s chi squared
bNo significant differences between groups except for ECOG-PS (EBUS group compared with Non-EBUS group, Fisher’s exact test, p = 0.009)
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NSCLC and SCLC patients, with a greater proportion of
Stage III NSCLC (30.7 %) and Limited SCLC (44.4 %)
patients undergoing EBUS-TBNA than other stages.
Number of invasive procedures per patient
A median of one invasive procedure was performed per
patient in both cohorts (Table 2) (p = 0.842). One inva-
sive procedure was sufficient to establish lung cancer
diagnosis for 68 % of patients in both cohorts. Invasive
procedures were not undertaken on 8.5 % of the patients
in the Pre-EBUS cohort and 9.8 % in the Post-EBUS co-
hort, for whom a diagnosis of lung cancer was made on
the basis of clinical presentation and imaging. Approxi-
mately 23 % of the patients in the Pre-EBUS cohort and
22 % of the Post-EBUS cohort had 2 or more invasive
procedures.
Six patients underwent both EBUS-GS and EBUS-
TBNA; five as part of a single procedure and in one case
EBUS-GS was undertaken with diagnostic purpose and
then followed up by EBUS-TBNA for staging. A single
EBUS-GS investigation was sufficient to establish lung
cancer diagnosis in 41.2 % (n = 14) of all EBUS-GS cases.
One patient (2.9 %) had two EBUS-GS procedures, nine
patients (26.5 %) underwent other invasive investigations
following EBUS-GS, and four patients (11.8 %) had inva-
sive procedures before EBUS-GS. The main reason for
additional invasive investigations among EBUS-GS pa-
tients was inadequacy of the preceding investigation/s.
One patient was referred for EBUS-CG for material for
molecular testing following positive result from a
bronchoscopy.
Approximately half of all patients undergoing EBUS-
TBNA (45.2 %, n = 28) also underwent additional inva-
sive investigations, both prior to and following the
EBUS procedure. Multiple procedures were required
for a number of reasons, including: non-diagnostic re-
sults from initial invasive investigations (19.4 %, n = 12);
non-diagnostic EBUS-TBNA results (9.7 %, n = 6); add-
itional material required for molecular testing (1.6 %, n
= 1); and EBUS-TBNA being conducted for staging pur-
poses only, following positive diagnosis from CT-
TTNAs and FBs (12.9 %, n = 8).
Complications
Across both cohorts, 36 % of CT-TTNAs resulted in
complications. Of 162 CT-TTNAs, 57 resulted in a
pneumothorax, one in pulmonary haemorrhage, and one
in intra-parenchymal bleeding. While only nine cases
with pneumothorax following CT-TTNA had chest tube
inserted, 32 patients were admitted for observation over-
night. Only one complication (a small pneumothorax)
occurred each as a result of bronchoscopy (N = 260) and
EBUS-GS (N = 34). EBUS-TBNA (N = 62) did not result
Table 2 Patients receiving invasive procedures, time to
management decision, and diagnostic procedures for the






n (%)a n (%)a
Invasive procedures
Bronchoscopy 135 (57.7) 131 (40.2) <0.001**
CT-TTNA 92 (39.3) 95 (29.1) 0.012*
EBUS 0 (0) 90 (27.6) <0.001**
Thoracentesis 26 (11.1) 24 (7.4) 0.125
Other invasive
procedures
30 (12.8) 47 (14.4) 0.588
Other surgical
procedures
9 (3.8) 13 (4.0) 0.932




≤ 28 days 154 (66.7) 245 (75.9)
> 28 days 77 (33.3) 78 (24.1) 0.018*








1 (0) 1 (0) 0.842e
Thoracentesis: thoracentesis, pleural effusion drainage, pleural biopsy
Other invasive procedures: FNA, US-FNA, EUS-FNA, biopsy other, CT
biopsy other
Other surgical therapeutic/diagnostic procedures: surgery for brain metastasis,
bone marrow trephine, spinal lesions
*p < 0.05, **p < 0.01
aNumber of patients
bNumber per patient
cExcludes 6 patients with no date of presentation available – unable to
establish time to management decision
dFisher’s exact test
eMann–Whitney U test; all other tests except d are Pearson’s chi squared test
Table 3 Number and stage of patients in the Post-EBUS cohort
(N = 326) who had EBUS
EBUS-GS group EBUS-TBNA group
Stage (n) n (%a) n (%a)
NSCLC
I (55) 9 (16.4) 6 (10.9)
II (23) 4 (17.4) 2 (8.7)
III (75) 9 (12.0) 23 (30.7)
IV (135) 12 (8.9) 21 (15.6)
SCLC
Limited (18) 0 (0) 8 (44.4)
Extensive (20) 0 (0) 2 (10.0)
Overall (326) 34 (10.4)b 62 (19.0)b
aPercentage within cancer stage
bIncludes 6 patients who had both EBUS-GS and EBUS-TBNA
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in any complications. Significantly fewer complications
occurred in the Post-EBUS cohort compared to the Pre-
EBUS cohort (9.0 % vs 15.3 %; χ2 = 4.931; p = 0.0264).
Time to management decision
The median TMD was 17 days for the Pre-EBUS cohort
and 13 days for the Post-EBUS cohort (p = 0.070)
(Table 2). In the Post-EBUS cohort, when EBUS was the
only invasive procedure undertaken, the median TMD
was comparable to the non-EBUS patients: 10 days for
both EBUS-GS and EBUS-TBNA (Table 4). However,
half of EBUS-TBNA patients (n = 28, 50.0 %) and EBUS-
GS patients (n = 14, 50.0 %) underwent EBUS before or
after other invasive investigations. For these patients,
median TMD was longer compared to patients with
EBUS only: 45 days for EBUS-GS (p = 0.001) and
26.5 days for EBUS-TBNA (p < 0.001) (Table 4). More
patients in the Post-EBUS cohort were diagnosed within
28 days of presenting at the hospital when compared to
the Pre-EBUS cohort (75.9 % vs 66.7 %; p = 0.018)
(Table 2).
A multiple logistic regression identified predictors of
TMD within 28 days. The total number of inpatient
visits, outpatient visits and imaging investigations
(Table 5) predicted a longer TMD. Thus, reduced odds
of TMD of less than 28 days occurred with higher num-
bers of inpatient visits (OR = 0.64, p = 0.020), outpatient
visits (OR = 0.37, p < 0.001) or imaging investigations
(OR = 0.81, p < 0.001). Conversely, patients with Stage III
(OR = 3.16, p = 0.002) or Stage IV (OR = 4.73, p < 0.001)
NSCLC had increased odds of TMD within 28 days
compared to those with Stage I NSCLC. Patients with
Limited (OR = 5.93, p = 0.011) or Extensive (OR = 4.64,
p = 0.009) SCLC had increased odds of TMD within
28 days compared to those with Stage I NSCLC. EBUS
was not an independent predictor of TMD within
28 days.
To assess change in practice patterns between the Pre-
and Post-EBUS cohort, we evaluated all NSCLC patients
with Stage I, II and III disease who had surgical resection
(Table 6). A higher proportion of patients with clinical
Stage II (N1 involvement) in the Post-EBUS cohort pro-
ceeded to surgery, compared with the Pre-EBUS cohort.
Discussion
The introduction of new diagnostic procedures has the
potential to prolong the diagnostic process and contrib-
ute to a delay in management decisions. However, this
retrospective pre/post study demonstrated that introduc-
tion of EBUS-GS and EBUS-TBNA for the diagnosis of
lung cancer at a tertiary teaching hospital in Western
Australia led to a decrease in the number of bronchos-
copies and CT-TTNAs and did not affect the TMD. The
Post-EBUS cohort had fewer complications, which may
be attributed to the decrease in the number of CT-
TTNAs, as no change in the proportion of complica-
tions resulting from CT-TTNAs was observed.
In our study, only one mediastinoscopy was performed
in the Pre-EBUS cohort and three in the Post-EBUS co-
hort. Mediastinoscopies were not routinely performed as
frequently as guidelines and their “gold standard” status
Table 4 Time to management decision for patients with EBUS as the only invasive investigation compared to patients with EBUS





















10 (28) 45 (48) 0.001* 10 (10.0) 26.5 (29) <0.001*
*p < 0.01
aexcludes 6 patients with both EBUS-GS and EBUS-TBNA
bincludes 1 patient with 2 EBUS-GS investigations
cMann–Whitney U test







EBUS 1.29 0.60 2.75 0.516
Total number of inpatient visits 0.64 0.44 0.93 0.020*
Total number of outpatient visits 0.37 0.29 0.48 <0.001**
Number of invasive procedures 0.65 0.39 1.08 0.096
Total number of imaging
investigations
0.81 0.72 0.91 <0.001**
NSCLC
Stage II 2.22 0.79 6.27 0.130
Stage III 3.16 1.54 6.52 0.002**
Stage IV 4.73 2.39 9.36 <0.001**
SCLC
Limited 5.93 1.51 23.27 0.011*
Extensive 4.64 1.48 14.61 0.009**
Comparisons: Time to diagnosis less than or equal to 28 days vs greater than
28 days, EBUS compared to non-EBUS, Stage compared to NSCLC Stage I
*p < 0.05, **p < 0.01
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would recommend [7, 8, 20]; perhaps over-reliance was
placed on CT and PET scans for staging of the mediasti-
num. In our study, all three patients who underwent me-
diastinoscopies in the Post-EBUS cohort had an EBUS
investigation prior to the mediastinoscopy and mediasti-
noscopies were the last investigation in a rigorous
workup required to determine precise stage of the dis-
ease and suitability for surgical treatment.
Our results show that diagnosis and staging of lung
cancer in the Pre-EBUS cohort was a two stage process,
with sampling of the peripheral lung mass by CT-TTNA
or FB, and staging of the mediastinum by PET scanning,
despite its limitations. Whilst mediastinoscopy was
rarely performed at our hospital, previous studies of pa-
tients with NSCLC have reported that evaluation of the
mediastinum by mediastinoscopy was infrequently per-
formed (27 %) in patients undergoing surgery [7, 8]. In
addition, a recent multicentre, pragmatic, randomised
controlled trial (RCT) substantiated that mediastinos-
copy is rarely needed for the pre-operative staging of
NSCLC in clinical practice [21]. A prospective clinical
trial by Navani et al. [22] suggests that EBUS-TBNA
may prevent 87 % of mediastinoscopies if routinely per-
formed for patients with mediastinal lymph node
involvement.
With regard to EBUS-TBNA staging of N2 nodes,
there were no false negative cases discovered at surgery.
A higher proportion of patients with clinical Stage II
(N1 involvement) in the Post-EBUS cohort proceeded to
surgery, compared with the Pre-EBUS cohort (Table 6).
Following the introduction of EBUS, there was an in-
crease in patients being considered for surgery; PET
scans are known to be oversensitive and thus may have
unnecessarily excluded some patients in the Pre-EBUS
cohort from having surgery.
Surgery is indicated for patients with Stage I or II dis-
ease and good performance status; hence, accurate staging
is essential to exclude mediastinal involvement. Patients
with an ECOG-PS of 3 or 4 are less suitable for radical
treatment and thus fewer patients would be referred for
EBUS-TBNA, as mediastinal staging is less critical. Con-
sistent with these recommendations, almost all EBUS pa-
tients in our study had ECOG-PS of 0, 1, or 2.
Radical chemo-radiotherapy with curative intent is in-
dicated for Stage III disease. Our findings show that a
higher proportion of Stage III NSCLC cases underwent
EBUS-TBNA when compared to the other stages. As
these patients are more likely to present with enlarged
lymph nodes on CT or PET imaging, EBUS-TBNA
would be the preferred invasive procedure, providing
both diagnostic and staging information simultaneously
with a lower risk of complication. EBUS-TBNA was
undertaken in almost half of the patients with limited
SCLC; such cases often have enlarged hilar or medias-
tinal lymph nodes, so EBUS-TBNA provides diagnostic
material.
Recommended timelines for diagnosis and start of treat-
ment for lung cancer have been included in several guide-
lines [23, 24] and are considered to be indicators of
quality of health-care. Whilst there is no established rela-
tionship between time to diagnosis or treatment and sur-
vival/recurrence in lung cancer patients, delays may
contribute to distress in patients and missed opportunities
to treat [25, 26]. Currently, Western Australian guidelines
recommend four weeks (28 days) from initial presentation
to specialist to initial treatment decision [27].
This study demonstrated that the median time from
initial presentation to management decision for lung
cancer patients decreased from 17 days for the Pre-
EBUS cohort to 13 days for the Post-EBUS cohort; how-
ever, this difference was not statistically significant. It is
important to emphasise that patients with suspected
lung cancer presented at the hospital via different path-
ways, although referral source was not a predictor for
the time taken from first presentation to final diagnosis
and treatment recommendations. A small number of
patients with suspicious pulmonary lesions on imaging,
required extensive work-up and long follow-up before a
definitive diagnosis was established. This may be
reflected in the regression analysis, which indicated that
a greater number of imaging investigations and inpatient
and outpatient visits were associated with TMD >28 days.
Furthermore, patients with Stage III and Stage IV
NSCLC and patients with SCLC had higher odds of
TMD of ≤28 days when compared to Stage I NSCLC.
This finding is consistent with the overall clinical man-
agement of patients with advanced lung cancer, who are
less likely to be suitable for radical treatment and require
less rigorous investigations to guide management deci-
sions, and hence, take less time to decide on a manage-
ment plan.
A recent multicentre, pragmatic, RCT showed that
routine use of EBUS-TBNA after a staging CT for sus-
pected lung cancer resulted in faster management
Table 6 NSCLC patients (stage I, II and III) with surgical
resection in the Pre-EBUS cohort compared to the Post-EBUS
cohort












I 16 (59.3) 11 (40.7) 36 (65.5) 19 (34.5) 0.378a
II 2 (16.7) 10 (83.3) 13 (56.5) 10 (43.5) 0.026a,*
III 5 (8.6) 53 (91.4) 3 (4.0) 72 (96.0) 0.228b
Total 23 (23.7) 74 (76.3) 52 (34) 101 (66)
*p < 0.05
aPearson’s chi squared test
bFisher’s exact test
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decisions with fewer investigations when compared with
conventional diagnosis and staging methods [21]. Our
study found that EBUS was not an independent pre-
dictor of shorter TMD when introduced into routine
clinical practice at a tertiary hospital providing a state-
wide service. However, median TMD in our pre-EBUS
cohort was 17 days, substantially less than the 29 days
reported by Navani et al. for patients receiving conven-
tional diagnosis and staging [21].
Our results also showed that in the Post-EBUS cohort,
for patients who had only a single EBUS (TBNA or GS)
investigation, median TMD was comparable to those
who had conventional invasive diagnostic and staging in-
vestigations. EBUS-TBNA alone provided diagnosis and
intra-thoracic regional staging in 50 % of cases and a
single EBUS-GS investigation was sufficient to establish
lung cancer diagnosis in 50 % of cases undergoing the
respective procedure.
For half of the EBUS cases, additional invasive diag-
nostic procedures were conducted to obtain a definitive
diagnosis and/or staging; these patients had a longer
TMD. This may be explained by the finding that greater
numbers of imaging procedures and occasions of service
were both predictors of increased TMD in the regression
analysis, and points toward the potential complexity of
some cases referred for EBUS.
While EBUS-GS provides diagnostic information only,
EBUS-TBNA may fulfil both diagnostic and staging pur-
poses, particularly in patients with suspected mediastinal
lymph node involvement, where evidence-based guide-
lines recommend sampling of the mediastinum as the
most appropriate first invasive test [20]. Multiple proce-
dures were required for a number of reasons, including:
non-diagnostic results from initial invasive investiga-
tions; additional material required for molecular testing
and concerns about extra-thoracic disease. Nine patients
in the second cohort had lung cancer diagnosis con-
firmed with either CT-TTNA, FB or EBUS-GS but fol-
lowing this, also underwent EBUS-TBNA. In these cases,
the EBUS-TBNA procedure was performed for the pur-
poses of staging, where prior to the introduction of
EBUS, this should have been confirmed with mediasti-
noscopy. Given that the mediastinoscopies were underu-
tilised at our hospital, such cases presenting in the first
cohort would most likely have been staged via PET
alone; therefore, while the availability of EBUS may have
led to additional procedures being performed in these
cases (and a subsequent delay in TMD), the advantage
of more accurate staging must be recognised.
In this study, EBUS procedures were undertaken in
28 % of newly diagnosed lung cancer patients, with EBUS
more likely to be undertaken in diagnostically challenging
cases. As experience with EBUS has developed, there has
subsequently been an increase in its use, such that EBUS
is now performed in approximately 74 % of lung cancer
patients at the hospital (unpublished results) for the pur-
poses of tissue acquisition and more accurate staging.
We recognise that our study has several limitations.
This was a single-centre retrospective study in one of
the largest tertiary hospitals in Western Australia that
services a diverse population of patients, some of whom
were referred from long distances and private practices
because it was the only site in Western Australia to per-
form EBUS at the time. As such, our study cohort may
not be representative of other practice. However, the di-
versity of referrals and the large geographic catchment
area of the patients included in the study support our as-
sumption that local variations are less likely to contrib-
ute to the reported findings, and that our results may be
generalisable to other institutions providing similar care.
Some may argue that the small number of mediastinos-
copies performed over both cohorts limits the study’s
generalisability. While we agree that mediastinoscopy has
traditionally been considered the “gold standard” for
lymph node sampling in patients with suspected lung can-
cer and mediastinal adenopathy, previous studies have re-
ported that mediastinoscopy has been widely underused
[7, 8] and more recent findings indicate that mediastinos-
copy is rarely needed for preoperative staging of NSCLC
in clinical practice. Furthermore, the latest guidelines from
the American College of Chest Physicians recommend
EBUS-TBNA as a primary invasive investigation over sur-
gical staging in lung cancer patients with suspected medi-
astinal lymph node involvement [20]. It should be,
however, recognised that the guidelines also recommend
that surgical staging be considered in cases where the clin-
ical suspicion of mediastinal node involvement remains
high after a negative result using a needle technique.
Conclusions
Our study shows that the introduction of EBUS to diag-
nose lung cancer was associated with a reduction in CT-
TTNAs, bronchoscopies, and complications resulting
from the invasive procedures. Furthermore, the institution
of EBUS did not extend TMD, which remains well within
current guidelines. In addition, EBUS alone provided suffi-
cient diagnostic and/or regional staging information in
50 % of both EBUS-TBNA and EBUS-GS cases.
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